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REVIEW ARTICLE 
Precision medicine is mainly about genome-driven 
clinical decision-making which is the use of genome 
data from the patient to decide on tailoring the best 
treatment for the patient. The completion of the human 
genome project in 2003 has paved the way for a deeper 
understanding of diseases at the molecular level. The 
term genomics medicine has since emerged as 
clinicians and researchers capitalized on the 
knowledge of the genome to improve the management 
of many diseases. In the past decade, the term 
personalized or precision medicine was introduced to 
represent the tailoring of treatment to each individual 
based on a person’s unique genetic makeup, 
environment and lifestyle [1]. The coining of the term 
precision medicine, as opposed to the more common 
term ‘personalised medicine’, was intended to 
highlight the principle that subgroups of patients could 
be defined, often by genomics, and given treatment in 
more specific ways [2]. In simple terms, it means 
giving the right treatment to the right patient at the 
right time with the right outcome. The concept is not 
entirely new as it has been applied before in the 
practice of blood transfusion where each patient is 
given the appropriate blood units based on their blood 
groups. However, the emergence of genome data has 
allowed a more comprehensive application of 
personalized medicine to make it more precise. The 
unravelling of the molecular events in certain diseases 
like cancers has also led to the development of targeted 
therapies. 
 
For a long time, doctors have been treating patients 
with the same disease using the same approach, the 
same drugs and the same dose. The outcomes of 
treatment have strongly suggested that the individual 
variation, especially the genetic variants which differ 
between individuals, must be taken into account and 
the one-size fits all approach is no more valid for many 
diseases. Studies have shown that anti-cancer drugs 
are effective in perhaps 25% of cases only, that 6-8% 
of patients given medications will have adverse 
reactions, that there is a wide variation in response to 
treatment from one patient to another despite giving 
the same dose (adjusted per kg body weight) of the 
same drug, and that many non-communicable diseases 
have the component of gene-environment interaction 
in terms of disease pathogenesis. It is time for 
clinicians to tailor the treatment individually not only 
based on the phenotype but also on the genotype of the 
disease, provided there is evidence to show the benefit 
of a personalized approach [3]. 
 
The advances in genome sequencing technologies, and 
the cheaper cost, has allowed more and more patients 
to be profiled at the molecular level. There are still a 
lot to be learned but certainly we know more than 
before. In the case of cancers, the whole genome 
sequencing of tumour tissues has enable us to 
understand that every tumour has its own molecular 
signature which has both prognostic value but also has 
allowed researchers to identify what is termed now as 
actionable or targetable mutations. The term ‘targeted 
therapy’, once labeled decades ago as the magic bullet 
for the treatment of cancer, is now a reality for many 
different types of cancer. Many tyrosine kinase 
inhibitors are now in the market and used to improve 
the outcome of cancer patients. 
 
Many developed nations have already launched big 
initiatives in precision medicine in the past 5 years. In 
2012, the Prime Minister of UK launched the 100,000 
Genomes project in England. The project aim was to 
sequence 100,000 genomes which will include 
cancers, rare diseases and also pathogens [4]. The 
project is spearheaded by the National Health Service 
(NHS) with extensive collaboration with top 
university hospitals and the industry. One of the 
earliest benefactor of the project was a young girl with 
a rare disorder. She presented with a history of seizures 
and despite many tests and investigations, the doctors 
failed to clinch a diagnosis. Whole genome 
sequencing was performed on her and both parents. 
The bioinformatics analysis on the sequence data 
revealed a deletion in one copy of her SLC2A1 gene. 
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This gene plays a role in the uptake of glucose into the 
brain cells. She was put on a ketogenic diet and her 
seizures have stopped. Another wonderful example is 
the case of 3 sisters who all developed breast cancers 
within a few years of each other. What was interesting 
is that they did not inherit the BRCA1 or BRCA2 
mutation. These were just two of the many examples 
how whole genome or whole exome sequencing has 
enabled the diagnosis of many rare diseases and 
cancers, and in a proportion of the patients, to identify 
the specific intervention as well. It is believed that the 
approach of precision medicine can solve between 30-
40% of rare diseases. 
 
In the USA, President Obama launched a precision 
medicine initiative (PMI) in 2015 with a USD215 
million grant, focusing on non-communicable 
diseases, including cancers, and also setting up of a 
Cohort project [5]. This initiative, similar to the UK 
100,000 genomes project, will also performed whole 
genome sequencing on selected diseases. This project 
was triggered by the meeting of a group of scientists, 
which included Dr. Francis Collins, the then director 
of the National Institutes of Health USA, with the 
president. The other central feature of the USA PMI is 
the establishment of a new 1-million-person cohort of 
individuals who are willing to contribute their data for 
scientific discovery. 
 
The precision medicine initiatives in both the UK and 
the USA, reflected how the political will as a key 
driver in making things happen. But in both cases too, 
the prime movers were the scientists and the doctors 
who share the same belief and vision as to how 
genomics and precision medicine will be able to 
change the way we treat patients. In the simple sense, 
this is the future of medicine. 
 
How is Malaysia responding to all these? There has 
been very little movement or response at the top level. 
We need a lot more resources if we were to adapt this 
precision medicine in big way. There are clear 
challenges here. Firstly, the cost of the genetic testing 
or genotyping of the diseases. This is not covered 
under our healthcare system and many of these tests 
will cost easily between RM2000-5000. Some 
laboratories are absorbing some of these tests under 
their research grants but this is truly not sustainable 
once the funds run out of money. What needs to be 
done is that if, and when, the health financing system 
is implemented in Malaysia, we hope that genetic 
testing will be covered by the insurance companies. 
The second challenge is that if the genetic testing 
identifies a targetable mutation, there will additional 
cost of the tyrosine kinase inhibitors or the precision 
treatment. Again at the moment, many of these drugs 
are not in the ‘blue’ book or the list of drugs which are 
given free hence this will be the out-of-pocket 
expenses for the patient which can run into thousands 
of ringgit. The third challenge is how genetic testing 
will impact on the eligibility for medical insurance 
coverage. In some countries, there is a law prohibiting 
the use of genetic data to deprive an individual from 
getting medical insurance coverage but in Malaysia 
there is none yet. This means that if someone tested 
positive for the BRCA1 gene, for susceptibility to the 
familiar breast cancer, then the individual will not be 
able to obtain medical insurance coverage. 
 
The 3 challenges mentioned in the previous paragraph 
are not insurmountable if someone takes the leadership 
to tackle them at the top level. If Malaysia wants to be 
an early adapter to precision medicine, we truly need 
someone to champion this and most importantly the 
political will, just like in the UK and the USA. 
 
At the UKM Medical Molecular Biology Institute 
(UMBI), Universiti Kebangsaan Malaysia, we have 
already started offering tests for precision medicine. 
We have recently performed whole exome sequencing 
on patients with Pendred syndrome and VACTERL-H 
syndrome and discovered disease-causing mutations 
in the cases [6]. Our institute is arguably the first in the 
country to offer whole exome or whole genome 
sequencing for rare diseases. UMBI is already offering 
pharmacogenetics testing for HLA-B*1502 [7]. UMBI 
is also already offering whole genome and whole 
exome sequencing services to a wide variety of 
patients including cancers and rare diseases. Our 
institute has also embarked on whole genome 
sequencing of colorectal cancers which is funded by a 
research grant from the Ministry of Higher Education. 
This project is the first and largest of its kind in the 
local setting.  
 
Let’s now have a peek at the scope of precision or 
personalized medicine and the various applications 
which will directly benefit the patients (Table 1). 
 
What are the resources needed to implement precision 
medicine? We certainly need good sequencing 
facilities which must also have skillful and 
knowledgeable geneticists, scientists and 
bioinformaticians. The bioinformaticians will develop 
to adapt the optimal analytical algorithms to suit the 
clinical needs. For precision medicine to be successful, 
it needs to be accurate as well hence the understanding 
of the genetic variation at the population level needs to 
be wide and deep. This is even more crucial in a 
country like Malaysia which has a large multi-ethnic 
population.  
 
The personalized and precision medicine approach is 
already driven by the genome sequencing technologies  
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Table 1. The scope of precision medicine and how it is applied. 
Scope Application 
Risk assessment Genetic testing will be able to reveal one’s predisposition to disease. One example is the 
BRCA1/2 gene testing which will identify those at high risk of developing breast cancer. 
Others include the APC gene which is the gene responsible for the familial adenomatous 
polyposis that in turn increases the risk of colon cancer. 
Diagnosis and 
classification 
Genetic testing will allow accurate diagnosis allowing individualized treatment strategy. 
For rare diseases and also diseases which are difficult to diagnose, the precision medicine 
approach will enable a diagnosis to be clinched in up to 40% of cases. For disease 
classification, a good example will be in primitive neuroectodermal tumours (PNET) 
which are common brain tumours in children. There is now a molecular classification of 
PNET which takes into account alteration in the FOXR2, CIC, MN1 and BCOR genes 
[8]. 
Prevention Genetic testing will also allow behaviour/lifestyle/treatment intervention to prevent 
disease. A good example is the detection of genetic variants or polymorphisms which 
confer a high risk of non-communicable diseases such as diabetes. Another example is 
the detection of Lynch syndrome which involves the testing of MLH1, MSH2, MSH6 and 
PMS2 genes [9]. Those who have mutations in these genes will have a 70% lifetime risk 
of getting colorectal cancer. 
Detection  Many cancers release nucleic acids and other biomarkers into the circulation. Detection of 
molecular markers circulating in the blood (liquid biopsy) will enable the early detection 
of cancer or also disease relapse. 
Treatment The most impactful example for precision medicine is in cancer treatment. Genomic 
characterization has in fact been standard of care for some time for lung adenocarcinoma: 
testing for specific epidermal growth factor receptor (EGFR) mutations and anaplastic 
lymphoma receptor tyrosine kinase (ALK) rearrangements allows the personalization of 
therapy with targeted kinase inhibitors, such as gefitinib for EGFR and crizotinib for 
ALK23,24 [10]. For cancer, one can do whole exome or whole genome sequencing to 
identify the actionable or targetable mutations [11]. Another option is to use customized 
cancer panels which covers a certain of number genes containing the candidate mutations. 
In cardiology, for patients with the Long QT syndrome, there is specific therapy for those 
who have SCN5A mutations.  
Another big application is in pharmacogenetics which is perhaps the first application of 
personalized medicine. A good example in practice now is the testing for HLA-B*1502 
polymorphism before commencing tegretol for patients with epilepsy. Patients who have 
this genetic variant will have a high risk of developing Stevens Johnson syndrome. 
Prognostication  Certain molecular profiles confer a poorer prognosis in certain diseases. For example, in 
paediatric patients with medulloblastoma, those in the WNT sub-group have an excellent 
outcome [12]. Serial fluid biopsies and molecular testing can help the active monitoring 
of disease response and disease progression. There are also gene expression panels to 
predict prognosis for colorectal cancer [13]. 
and also Big Data. As we accrue more sequencing data 
from patients, we will learn more about the diseases 
and potentially this can lead to better approaches to 
management. Whether Malaysia is ready or not, 
precision medicine is already here for us to utilize and 
leverage on for the benefit of our patients. At this 
moment, it is very much for those who are subsidized 
or those who can afford to pay for the genetic testing 
and the cost of the subsequent targeted therapies. 
There is certainly a need to do cost-effectiveness and 
cost-benefit analysis and present the information to the 
relevant authorities and to convince them that 
precision medicine is the way forward.
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